Trials Sponsors Conditions Drugs Pricing

Conditions

Autoimmune Blistering Disease Pemphigus Vulgaris Skin Erosion

Keywords

pemphigus vulgaristopical insulinwound healingInsulin GlargineRegular InsulinAutoimmune Blistering DiseaseErosions

Outcome Measures

Primary Outcomes (1)

Time to Complete Healing
Number of days required for complete epithelialization of the lesion
Up to 14 days

Secondary Outcomes (2)

Lesion Surface Area Reduction
Baseline, Day 7, Day 14
Daily Healing Rate
14 days

Study Arms (3)

Long-acting insulin (LA)

EXPERIMENTAL

Lesions treated with topical insulin glargine (Lantus) 0.1 mL per 10 cm² twice daily

Drug: insulin glargine

Regular human insulin (SA)

EXPERIMENTAL

Lesions treated with topical regular insulin (Actrapid) 0.1 mL per 10 cm² twice daily

Drug: human insulin

control

PLACEBO COMPARATOR

Lesions treated with topical 0.9% normal saline 0.1 mL per 10 cm² twice daily

Drug: 0.9% Normal Saline

Interventions

insulin glargineDrug

Topical application of insulin glargine (100 IU/mL) at dose of 0.1 mL per 10 cm² lesion area, applied twice daily using insulin syringe spray technique for 14 days or until complete healing

Also known as: lantus

Long-acting insulin (LA)

human insulinDrug

topical application of regular insulin (100 IU/mL) at dose of 0.1 mL per 10 cm² lesion area, applied twice daily using insulin syringe spray technique for 14 days or until complete healing

Eligibility Criteria

Age18 Years+

Sexall

Healthy VolunteersNo

Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

Confirmed diagnosis of pemphigus vulgaris by clinical and histopathological criteria
Presence of erosions and/or ulcers on skin and/or mucous membranes

Sponsors & Collaborators

Alexandria University
Otherlead

Study Sites (1)

Alexandria main university hospital, Department of Dermatology and Venereology

Alexandria, 22301, Egypt

MeSH Terms

Conditions

PemphigusInsulin Resistance

Interventions

Insulin GlargineInsulinSaline Solution

Condition Hierarchy (Ancestors)

Skin Diseases, VesiculobullousSkin DiseasesSkin and Connective Tissue DiseasesAutoimmune DiseasesImmune System DiseasesHyperinsulinismGlucose Metabolism DisordersMetabolic DiseasesNutritional and Metabolic Diseases

Study Officials

Tarek M Hussein, MB BCh, MD
University of Alexandria
PRINCIPAL INVESTIGATOR
Carmen I Farid, MB BCh, MD
University of Alexandria
PRINCIPAL INVESTIGATOR

Enrollment

20 participants (actual enrollment reported by the registry).

Study Design

Study Type: interventional
Phase: phase 2
Allocation: RANDOMIZED
Masking: SINGLE
Who Masked: PARTICIPANT
Purpose: TREATMENT
Intervention Model: PARALLEL
Sponsor Type: OTHER
Responsible Party: SPONSOR

Study Record Dates

First Submitted

March 5, 2026

First Posted

March 10, 2026

Study Start

June 22, 2024

Actual (reported)

Effect of Topical Insulin on Healing Rate of Pemphigus Lesions

Brief Summary

Registry Overview

Trial Relationships

Study Timeline

Study Start

Primary Completion

Study Completion

First Submitted

First Posted

Conditions

Keywords

Outcome Measures

Primary Outcomes (1)

Secondary Outcomes (2)

Study Arms (3)

Long-acting insulin (LA)

Regular human insulin (SA)

control

Interventions

Eligibility Criteria

You may qualify if:

Sponsors & Collaborators

Study Sites (1)

MeSH Terms

Conditions

Interventions

Condition Hierarchy (Ancestors)

Study Officials

Enrollment

Study Design

Study Record Dates

You may not qualify if:

Intervention Hierarchy (Ancestors)

Data Sharing

Source record

Locations

Brief Summary

Registry Overview

Trial Relationships

Related Scientific Literature

Study Timeline

Study Start

Primary Completion

Study Completion

First Submitted

First Posted

Conditions

Keywords

Outcome Measures

Primary Outcomes (1)

Secondary Outcomes (2)

Study Arms (3)

Long-acting insulin (LA)

Regular human insulin (SA)

control

Interventions

Eligibility Criteria

You may qualify if:

Sponsors & Collaborators

Study Sites (1)

MeSH Terms

Conditions

Interventions

Condition Hierarchy (Ancestors)

Study Officials

Enrollment

Study Design

Study Record Dates

You may not qualify if:

Intervention Hierarchy (Ancestors)

Data Sharing

Source record

Locations